Page last updated: 2024-08-26

olivacine and s 16020-2

olivacine has been researched along with s 16020-2 in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (50.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Atassi, G; Bisagni, E; Burbridge, M; Guilbaud, N; Jan, M; Kraus-Berthier, L; Pierré, A; Rouillon, MH; Saint-Dizier, D; Visalli, M	1
Atassi, G; Jacquemin-Sablon, A; Le Mée, S; Markovits, J; Pierré, A; Saucier, JM	1
Berlion, M; Bourhis, J; Eschwege, F; Frascogna, V; Lucas, C; Maggiorella, L; Poullain, MG; Razy, SD	1
Awada, A; Bleiberg, H; Brillanceau, MH; Calvo, F; De Valeriola, D; Dosquet, C; Eftekhary, P; Gerard, B; Giacchetti, S; Giroux, B; Lucas, C; Marty, M; Piccart, M; Poullain, MG; Soudon, J	1

Trials

1 trial(s) available for olivacine and s 16020-2

Article	Year
Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules. Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12 Topics: Adult; Aged; Biological Availability; Carbazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Ellipticines; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyridines; Risk Assessment; Sensitivity and Specificity; Treatment Outcome	2002

Article

Year

Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules.

Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

Topics: Adult; Aged; Biological Availability; Carbazoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Ellipticines; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyridines; Risk Assessment; Sensitivity and Specificity; Treatment Outcome

2002

Other Studies

3 other study(ies) available for olivacine and s 16020-2

Article	Year
In vivo antitumor activity of S 16020-2, a new olivacine derivative. Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:6 Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Blood Cell Count; Bone Marrow; Breast Neoplasms; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Ellipticines; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Leukemia P388; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Tumor Cells, Cultured	1996
S16020-2, a new highly cytotoxic antitumor olivacine derivative: DNA interaction and DNA topoisomerase II inhibition. Molecular pharmacology, 1998, Volume: 53, Issue:2 Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line; Cell Survival; Circular Dichroism; Cricetinae; DNA; DNA Damage; DNA Ligases; Ellipticines; Spectrophotometry, Ultraviolet; Topoisomerase II Inhibitors	1998
The olivacine S16020 enhances the antitumor effect of ionizing radiation without increasing radio-induced mucositis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:7 Topics: Animals; Antineoplastic Agents, Phytogenic; Carbazoles; Cell Division; Combined Modality Therapy; Ellipticines; Female; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Mouth Mucosa; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Pyridines; Radiotherapy; Stomatitis; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2001